Maynard Um
-
-
-
-
-
-
-
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss of $0.42
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Rapport Therapeutics (RAPP): "see the X-TOLE2 readout as having no readthrough"
-
-
-
-
-
-
-
Rapport Therapeutics shares post hoc analysis of RAP-219 seizure drug
-
-
-
-
-
-
-
Rapport Therapeutics (RAPP) PT Raised to $77 at Citizens JMP
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Rapport Therapeutics (RAPP)
-
-
-
-
-
-
-
Jones Trading Starts Rapport Therapeutics (RAPP) at Buy
-
-
-
-
431,632 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

